+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Atopic Dermatitis Drugs Market Research Report by Route of Administration - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4904629
  • Report
  • June 2020
  • Region: Global
  • 239 pages
  • 360iResearch™
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Atopic Dermatitis Drugs Market to Grow USD 8,809.40 Million by 2025, at a CAGR of 5.80%


  • Astellas Pharma Inc.
  • Bayer HealthCare
  • Encore Dermatology
  • LEO Pharma
  • Meda AB
  • Mylan
  • MORE
The Global Atopic Dermatitis Drugs Market is expected to grow from USD 6,277.73 Million in 2019 to USD 8,809.40 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.80%.

Market Segmentation & Coverage:

This research report categorizes the Atopic Dermatitis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Route of Administration, the Atopic Dermatitis Drugs Market is examined across Injectable ROA, Oral ROA, and Tropical ROA.

On the basis of Geography, the Atopic Dermatitis Drugs Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Atopic Dermatitis Drugs Market including Astellas Pharma Inc., Bayer HealthCare, Encore Dermatology, LEO Pharma, Meda AB, Mylan, Novartis AG, Valeant, and Valent Pharmaceutical Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Atopic Dermatitis Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Atopic Dermatitis Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Atopic Dermatitis Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Atopic Dermatitis Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Atopic Dermatitis Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Atopic Dermatitis Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Atopic Dermatitis Drugs Market?
Note: Product cover images may vary from those shown
2 of 3


  • Astellas Pharma Inc.
  • Bayer HealthCare
  • Encore Dermatology
  • LEO Pharma
  • Meda AB
  • Mylan
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Route of Administration Outlook
3.3. Geography Outlook
3.4. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Atopic Dermatitis Drugs Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Atopic Dermatitis Drugs Market, By Route of Administration
7.1. Introduction
7.2. Injectable ROA
7.3. Oral ROA
7.4. Tropical ROA

8. Americas Atopic Dermatitis Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Atopic Dermatitis Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand

10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding

12. Company Usability Profiles
12.1. Astellas Pharma Inc.
12.2. Bayer HealthCare
12.3. Encore Dermatology
12.4. LEO Pharma
12.5. Meda AB
12.6. Mylan
12.7. Novartis AG
12.8. Valeant
12.9. Valent Pharmaceutical Inc.

13. Appendix
13.1. Discussion Guide
13.2. Edition Details
13.3. License Details
13.4. Pricing Details
Note: Product cover images may vary from those shown
3 of 3
  • Astellas Pharma Inc.
  • Bayer HealthCare
  • Encore Dermatology
  • LEO Pharma
  • Meda AB
  • Mylan
  • Novartis AG
  • Valeant
  • Valent Pharmaceutical Inc.
Note: Product cover images may vary from those shown